Somatic IL4R Mutations in Primary Mediastinal Large B-cell lymphoma lead to constitutive JAK-STAT signaling activation

Elena Viganò, Jay Gunawardana, Anja Mottok, Tessa Van Tol, Katina Mak, Fong Chun Chan, Lauren Chong, Elizabeth Chavez, Bruce Woolcock, Katsuyoshi Takata, David Twa, Hennady P Shulha, Adèle Telenius, Olga Kutovaya, Stacy S Hung, Shannon Healy, Susana Ben-Neriah, Karen Leroy, Philippe Gaulard, Arjan DiepstraRobert Kridel, Kerry J Savage, Lisa Rimsza, Randy Gascoyne, Christian Steidl

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)

Abstract

Primary mediastinal large B cell lymphoma (PMBCL) is a distinct subtype of diffuse large B cell lymphoma thought to arise from thymic medullary B cells. Gene mutations underlying the molecular pathogenesis of the disease are incompletely characterized. Here, we describe novel somaticIL4Rmutations in 15 out of 62 primary cases of PMBCL (24.2%) and in all PMBCL-derived cell lines tested. The majority of mutations (11/21; 52%) were hotspot single nucleotide variants in exon 8 leading to an I242N amino acid change in the transmembrane domain. Functional analyses establish this mutation as gain-of-function leading to constitutive activation of the JAK-STAT pathway and upregulation of downstream cytokine expression profiles and B cell specific antigens. Moreover, expression of I242N mutant IL4R in a mouse xenotransplantation model conferred growth advantagein vivoThe pattern of concurrent mutations within the JAK-STAT signaling pathway suggests additive/synergistic effects of these gene mutations contributing to lymphomagenesis. Our data establishIL4Rmutations as novel driver alterations and provide a strong preclinical rationale for therapeutic targeting of JAK-STAT signaling in PMBCL.

Original languageEnglish
Pages (from-to)2036-2046
Number of pages11
JournalBlood
Volume131
Issue number18
DOIs
Publication statusPublished - 3-May-2018

Keywords

  • Journal Article

Cite this